Journal article
OA-21 Dynamic Frailty Analysis of Transplant-Ineligible (TIE) Patients with NDMM in the Phase 3 MAIA and CEPHEUS Trials of Daratumumab (Dara) + Lenalidomide-Dexamethasone (Rd) and Bortezomib-Rd (VRd)
Authors
Mian H; Facon T; Cook G; Moreau P; Usmani S; Kumar S; Manier S; Hungria V; Bahlis N; Pei H
Journal
Clinical Lymphoma Myeloma & Leukemia, Vol. 25, , pp. s14–s15
Publisher
Elsevier
Publication Date
September 1, 2025
DOI
10.1016/s2152-2650(25)03425-1
ISSN
2152-2650